Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Non-clear cell renal cell carcinomas (RCCs) represent up to 25% of kidney cancers, exhibiting significant heterogeneity.
• These distinct subtypes possess unique pathological features, molecular alterations, and varying responses to systemic therapies.

Purpose of the Study:

• To delineate the specific oncogenic mechanisms and molecular characteristics of various non-clear cell RCC subtypes.
• To review the current landscape and future directions of systemic therapy for these rare kidney cancers.

Main Methods:

• Review of recent advances in molecular biology and collaborative research.
• Analysis of genomic alterations and pathway dysfunctions in specific RCC subtypes.
• Evaluation of systemic therapy efficacy and investigational strategies.

Main Results:

• Papillary RCCs show distinct subsets with specific gene expression, chromatin remodeling, cell cycle, and MET pathway alterations.
• Chromophobe RCCs exhibit metabolic pathway and mitochondrial dysfunction.
• Translocation RCCs are defined by MITF fusions, while collecting duct carcinomas show T-cell infiltration and metabolic changes. Medullary RCCs have INI1 gene alterations, and sarcomatoid RCCs display mesenchymal dedifferentiation.

Conclusions:

• Current VEGF and mTOR inhibitors show limited efficacy in non-clear cell RCCs compared to clear cell RCCs.
• Targeted therapies like MET, CDK4/6, and EZH2 inhibitors, along with immune checkpoint inhibitors, are under investigation.
• Improved patient stratification and understanding of molecular drivers are essential for advancing treatment for rare RCCs.